Enzene Biosciences, a biotech subsidiary of Alkem Labs, one of India’s top five pharmaceutical companies, has launched a new manufacturing facility in the US. The facility, located in New Jersey, has been established with an investment of $70 million. This move follows President Donald Trump’s calls to pharmaceutical companies to increase local manufacturing and create employment opportunities. Currently, the facility has hired 50 people, with plans to expand its workforce to 200 employees over time.
According to Himanshu Gadgil, CEO of Enzene Biosciences, the company has developed a connected continuous manufacturing technology, known as EnzeneX, which offers significant cost efficiencies and faster processing compared to traditional batch-wise biotech drug manufacturing. This technology has been developed indigenously by Enzene and is now being implemented in the US facility.
Gadgil sees this development as a reflection of Enzene’s growth and the strength of India’s scientific ecosystem. He believes that this technology has the potential to contribute transformative solutions to the world. The establishment of the US facility is a significant milestone for Enzene, marking its expansion into the global market.
The connected continuous manufacturing technology developed by Enzene is expected to revolutionize the biotech drug manufacturing process. By offering cost efficiencies and faster processing, this technology has the potential to increase the availability of biotech drugs and reduce their costs. The implementation of this technology in the US facility is expected to have a positive impact on the global biotech industry.
Overall, Enzene’s launch of its US manufacturing facility is a significant development in the biotech industry. The company’s investment in the US market and its commitment to developing innovative technologies are expected to drive growth and expansion in the years to come. With its strong foundation in India and its expanding presence in the global market, Enzene Biosciences is poised to become a major player in the biotech industry.